Valeant’s Permax withdrawn
Executive Summary
Valeant Pharmaceuticals will voluntarily withdraw its Parkinson's disease therapy Permax (pergolide) due to the high rate of heart valve damage associated with the drug, FDA announces March 29. The agency requested the withdrawal due to results of two studies published in the January issue of the New England Journal of Medicine that showed a five-fold increase in the risk of valvulopathy. Generic versions of Permax, marketed by Par and Teva, will also be withdrawn...
You may also be interested in...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.